Targeted Product Development: Personalized Medicine versus Orphan Product Development

Format: External webinar | Document type: Webinar

The development of therapeutics for personalized medicine leverages many of the advantages of the legislation conferred upon orphan products. New products must be positioned intelligently to take advantage of this legislation. Join David Shoemaker, Ph.D. as he discusses the benefits of orphan product designation in the US, EU, and strategies for obtaining these designations for novel products.


David Shoemaker David Shoemaker Senior Vice President R&D

Related resources from Rho

Supplier info centre